Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519145 | 0.79 | TLR8 (0.42) | HRH4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL16139312 | 0.76 | TLR8 (0.51) | HRH4NUDT1TLR8HRH3 | |
| SCHEMBL1588211 | 0.75 | ESR1 (0.62) | HRH4ESR1 | |
| SCHEMBL3450728 | 0.75 | NUDT1 (0.65) | HRH4NUDT1TLR8HRH3 | |
| SCHEMBL4647318 | 0.74 | HRH4 (0.48) | HRH4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL15534955 | 0.74 | CYP1A2 (0.49) | HRH4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL14619916 | 0.74 | TLR8 (0.66) | HRH4NUDT1TLR8HRH3 | |
| SCHEMBL3406133 | 0.73 | NUDT1 (0.51) | HRH4CYP2C19CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL21003173 | 0.73 | HRH4 (0.47) | HRH4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL14621314 | 0.73 | HRH3 (0.53) | HRH4NUDT1TLR8HRH3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20060252748-A1 | Use of CDK II inhibitors for birth control | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006087230-A1 | USE OF CDK II INHIBITORS FOR FERTILITY CONTROL | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | WO | disclosed |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1392662-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096888-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | HRH4 2955/4885CYP1A2 1015/4885CYP3A4 1916/4885 |
| US-20060252748-A1 | Use of CDK II inhibitors for birth control | CDK6, CDK2, CDKL2 | HRH4 3638/4885CYP1A2 264/4885CYP3A4 1016/4885 |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | HRH4 3004/4885CYP1A2 981/4885CYP3A4 1946/4885 |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | HRH4 2733/4885CYP1A2 1009/4885CYP3A4 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.